Ann: Otto Buttula appointed to the Board of OncoSil, page-11

And he will have more.

He is currently sitting on significant losses as are all shareholders.

From my brief reading, he generally gets involved in undervalued companies with prospects, pushes them, and then participates heavily in the capital raises to increase his holdings.

Same situation here. The company is undervalued, needs a push, has a product, and he will increase his holdings during the inevitable CR that will come.

There are biomedtech investors who follow his lead and so I hope some positive effect will flow to OSL.

And I agree with the relative silence from management. I want them to report real advances. The reason I'm still here is that the management team is good and I am backing FDA HDE approval for cholangio. My assessment is that it will be granted once they have submitted the full dataset from Panco. That will rerate the sp, but sadly rerating from 6c will be less significant than rerating from 10 or 12c.